BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Sanofi  Pasteur  MSD  SNC  submitted  on  29  September  2004  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  ProQuad,  through  the 
centralised procedure. After agreement by the CHMP on   25 April 2002, this medicinal product  has 
been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. Manfred Haase 
Co-Rapporteur:  Dr. Pasqualino Rossi 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 October 2004 
The Rapporteur's first assessment report was circulated to all CHMP Members on 28 December 
2004.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CHMP  Members  on  
28 December 2004 
During  the  meeting  on  14-17  February  2005  the  CHMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
company on 17 February 2005 
The company submitted the responses to the consolidated list of questions on 13 April 2005 
The  summary report  of the inspection  carried  out  at the  manufacturing site Marck &  Co. Inc, 
770  Sumneytown  Pike,  West  Point,  Pennsylvania  19486  between  8  –  10  February  2005  was 
issued on 2 May 2005 
The  Rapporteurs  circulated the response assessment report  on the  company’s  responses  to the 
list of questions to all CHMP Members on 20 May 2005 
The Biologics Working Party during its meeting of 13 - 15 June 2005 adopted the BWP Report 
to be transmitted to the CHMP for endorsement 
During  the  CHMP  meeting  on  20-23  June  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the company 
The Vaccines Working Party during its meeting of 6 - 7 July 2005 adopted the VWP Report to 
be transmitted to the CHMP for endorsement 
The company submitted the responses to the CHMP list of outstanding issues on 11 July 2005 
During the CHMP meeting on 25-28 July 2005, the CHMP agreed on a 2nd list of outstanding 
issues to be addressed in writing by the company 
The company submitted the responses to the 2nd list of outstanding issues on 29 August 2005 
The Rapporteurs circulated the Joint Assessment Report on the company’s responses to the List 
of outstanding issues to all CHMP members on 2 September 2005 
The  Biologics  Working  Party  during  its  meeting  of  5-7  September  2005  adopted  the  BWP 
Report to be transmitted to the CHMP for endorsement 
During  the  meeting  on  12-15  September  2005  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to ProQuad on 15 September 2005. The company provided 
1/2 
EMEA 2006 
 
 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on 
12 September 2005  
• 
• 
• 
Further  to  the  outcome  of  the  Standing  Committee  meeting  held  on  13  February  2006,  the 
European Commission referred the Proquad CHMP opinion back to the CHMP on 15 February 
2006 for further examination of the different storage conditions of the powder and the solvent. 
During  the  meeting  on  21-23  February  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted and the scientific discussion within the Committee, issued a revised positive opinion 
for granting a Marketing Authorisation to ProQuad on 23 February 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 6 April 2006. 
2/2 
EMEA 2006 
 
 
